Interaktiver GCP- Kurs und Prüfarzttraining

Größe: px
Ab Seite anzeigen:

Download "Interaktiver GCP- Kurs und Prüfarzttraining"

Transkript

1 Where science and ethics meet Interaktiver GCP- Kurs und Prüfarzttraining 23 & 24. März 2011 Bonn, Deutschland -

2

3 The European Forum for Good Clinical Practice where science and ethics meet Interaktiver GCP-Kurs und Prüfarzttraining AGENDA Mittwoch, 23. März :00 Die Entwicklung der GCP-Grundsätze 09:20 Vom ICH-GCP-Standard zur deutschen Gesetzgebung für klinische Prüfungen, Diskussion 09:55 Ethische Begutachtung und Ethikkommissionen, Diskussion 11:05 Kaffeepause 11:30 Die deutsche Gesetzgebung für klinische Prüfungen, Diskussion 12:30 Mittagspause 13:30 Vorbereitung einer klinischen Prüfung im Prüfzentrum, Diskussion 14:45 Qualitätsmanagement in klinischen Prüfungen, Diskussion 15:30 Kaffeepause 16:00 Grundsätze des Dokumenten-Managements, Diskussion 17:00 Ende Tag 1 Donnerstag, 24. März :30 Einschluss von Studienteilnehmern in klinische Prüfungen, Diskussion 09:15 Wichtige Aspekte bei der Durchführung klinischer Studien, Diskussion 10:15 Kaffeepause 10:45 Was passiert, wenn es schiefläuft? Diskussion 11:15 Zuverlässige Meldung von Nebenwirkungen 12:00 Abschluss-Quiz 12:30 Ende des Workshops

4

5 where science and ethics meet PRESENTATION OF THE EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE INTRODUCTION The European Forum for Good Clinical Practice (EFGCP) was founded during a conference at the European Parliament in 1993 with the support of the European Commission. Since its creation, EFGCP has functioned as a leading European think tank for discussion, research, and critical evaluation in the development of European health research. EFGCP is a non-profit organisation established by and for individuals with a professional involvement in the conduct of biomedical research. Its purpose is to promote Good Clinical Practice (GCP) and encourage the practice of common, high-quality standards in all stages of biomedical research throughout Europe. VISION Promote medical and pharmaceutical progress in Europe and elsewhere by fostering partnerships between groups and entities involved in clinical science and ethics across disciplines and cultures. MISSION EFGCP s mission is to promote the interests of patients in clinical research through the development of European ethical and scientific standards. The EFGCP provides a common meeting ground for the many disciplines and organisations affected by GCP. The primary aims of the EFGCP are to promote the highest standards for Good Clinical Practice (GCP) in Europe and abroad, to promote open discussion on critical issues in biomedical research and health, to promote education and awareness leading to the application of rigorous ethical and scientific requirements in clinical research, to facilitate the transfer of knowledge and skills across disciplines and sectors, to promote a renewed emphasis on human values in research involving human participants.

6 The EFGCP is a European organisation with a global vision. This is reflected in the many collaborative partnerships it has developed with European, North American and International Research patient, research, and regulatory organisations. FUNDING The basic source of funds for the EFGCP is membership fees. Additional funding for specific EFGCP activities is developed according to the objectives and scope of the activity concerned. In order to maintain its independence and high ethical standards, the EFGCP actively seeks funding across a wide range of funding organisations, including public (i.e. EU funded-projects) and private institutions. All EFGCP financial engagements are guided by the principles of independence in decision-making and transparency. STRUCTURE MEMBERSHIP Membership in the EFGCP is open to professionals and individuals, representing patient groups, ethics committees, academic & industry research enterprises, regulatory officials, and those concerned to develop Good Clinical Practice in Europe. BOARD The EFGCP is governed by a Board of Directors. The Board has responsibility for providing leadership, policy-making, and financial decision-making in accordance with the Charter of Incorporation. Board members are elected by the EFGCP General Assembly. The members are elected for a term of 3 years, which is renewable. The Board is responsible to ensure that the EFGCP is managed to continually comply with the ethical and scientific standards required for providing European leadership in Good Clinical Practice.

7 SCIENCE & ETHICS COUNCIL The EFGCP Science & Ethics Council is composed of leading European and international experts representing major institutions affecting the regulation and practices of Good Clinical Practice. It pools the efforts of the Board including the Working Parties chairpersons and the previous Advisory Council under one same roof. Although the executive power of the EFGCP continues to rest with the Board, the Council takes the lead in matters of Science and Ethics. The Working Parties which would like to broaden their activities, issue more position papers and propose topics for conference receive recommendations and approval from the new Council. The Science & Ethics Council contributes to the development of the EFGCP by increasing input into EFGCP planning and projects, extending the EFGCP basis of expertise and competence, and increasing the awareness and recognition of the contributions to GCP made by the EFGCP. The Science and Ethics Council sees to optimally reflect the various components of the clinical research community: the patient associations, the sponsors, the CROs, the investigators and their networks, the ethics committees and the authorities. By itself, the new Council with 2 meetings a year will provide a unique opportunity for Forum discussions. The members of the Science & Ethics Council are regularly invited to participate in EFGCP Events either as experts in particular subjects or in advisory capacity for developing the events WORKING PARTIES The EFGCP Working Parties serve as the central reference point for EFGCP research and the development of European guidances, reports, and publications in the area of Good Clinical Practice. The Working Parties are composed of EFGCP members with expertise and interest in contemporary areas such as the ethics, science, and regulation of clinical research in Europe and globally. The following six Working Parties are active: Ethics Working Party Audit Working Party Education Working Party Children's Medicines Working Party Geriatric Medicines Working Party Patients Roadmap to Treatment Working Party (in collaboration with the European Genetic Alliance Network EGAN) BUREAU The EFGCP Secretariat is the organisational arm of the EFGCP responsible for all the operations of the association and its membership services. The EFGCP events are also managed internally.

8 ACTIVITIES To fulfill its mission it is necessary for the EFGCP to organise relevant activities. Activities include Conferences, Workshops, Working Parties, Research Projects (FP6/FP7/IMI), Website, Newsletter and other publications. PUBLICATIONS EFGCP is dedicated to bringing leading publications on GCP in Europe and abroad. The EFGCP publishes its own newsletter, The EFGCP News, quarterly as well as a number of European guidelines and key reports (Annual update of the EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe, freely available on the website) CONFERENCES & WORKSHOPS Since its creation, EFGCP has been organising a significant number of conferences and workshops which consist in high level forum discussions characterised by interactive debates on a specific topic with the major stakeholders in the selected area. Among the organisations that have participated in projects led by the EFGCP are the European Commission, the European Parliament, EMA, EORTC, ESF, EAP, EPPOSI, EuropaBio, EFPIA, ICH, BARQA, WMA, CIOMS, the Faculty of Pharmaceutical Medicine, etc. Please consult the list of past events for further details. OFFICE & CONTACT PERSON: Fanny Senez Chief Operating Officer EFGCP Secretariat Square de Meeûs Rue de l Industrie 4 B-1000 Brussels Belgium Tel Fax Website: FOR MORE DETAILS ON EFGCP, PLEASE VISIT OUR WEBSITE:

9 Where science & ethics meet CV OF EFGCP EXPERT Dr. med. Ingrid KLINGMANN FFPM, studied medicine in Germany and specialized in General Medicine, Clinical Pharmacology and Pharmaceutical Medicine. After having joined pharmaceutical industry as medical advisor, she held senior management positions in different international contract research organisations and was responsible for operational, scientific, regulatory and business aspects of international clinical research projects from Phase I to Phase IV. Since January 2003 she has her own pharmaceutical development and site management support consulting company. From January 2004 to July 2007 she was also CEO of two investigative sites in London, UK, performing clinical trials in acute and chronic pain as well as musculo-skeletal diseases. Dr. Klingmann is a founding member and Chairman of the Board of the European Forum for Good Clinical Practice (EFGCP) as well as Co-Chair of the EGAN/EFGCP Working Party Patients Roadmap to Treatment. On behalf of EFGCP she was the Project Coordinator for the FP7-funded ICREL project. She is a founding member of the Association for Applied Human Pharmacology (AGAH) in Germany where she also established and chaired the Ethics Working Party of this organisation dealing with ethics and GCP issues in Human Pharmacology in Germany; today she is chairing AGAH s regulatory affairs working party and is President; and in the Drug Information Association (DIA) she was a member of the Steering Committee Europe (now Advisory Council Europe), a former chair person of the SCE, a Member of the Board, a Member of the Foundation Board, and speaker, session chair and programme committee member for numerous conferences of the DIA. Dr. Klingmann chairs the clinical research module of the post-graduate Master in Regulatory Affairs course at the University of Bonn, Germany as well as the Diploma Course in Clinical Trail Practices at the University of Basel, Switzerland.

10

11 Die Entwicklung der GCP-Grundsätze

12

13 Interaktiver GCP-Kurs und Prüfarzttraining Dr. med. Ingrid Klingmann Pharmaplex bvba Brüssel, Belgien Die Entwicklung der GCP-Grundsätze Dr. med. Ingrid Klingmann Material erstellt in Zusammenarbeit mit Prof. Dr. JanHasker G. Jonkman University of Groningen, The Netherlands CONTENT GOOD CLINICAL PRACTICE (GCP): ICH DEFINITION OF GCP DECLARATION OF HELSINKI IMPORTANT ASPECTS OF GCP ICH GUIDELINE FOR GCP OTHER GUIDELINES CONCLUSIONS 3/37

14 GOOD CLINICAL PRACTICE (GCP): ICH (1) Key document for Good Clinical Practices Guideline for Good Clinical Practice (Topic E6) International Conference on Harmonisation (ICH) = NEW WORLD STANDARD Since /37 GOOD CLINICAL PRACTICE (GCP): ICH (2) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (first meeting in 1991, Brussels, Belgium): Objectives: more economical use of human, animal and material resources elimination of unnecessary delay in the global development and availability of new medicines, maintaining safeguards on quality, safety and efficacy and regulatory obligations to protect public health 5/37 GOOD CLINICAL PRACTICE (GCP): ICH (3) 6/37 Composition: representatives of regulatory agencies and pharmaceutical industries of triad: EU USA Japan Observers of: WHO Canada EFTA

15 GOOD CLINICAL PRACTICE (GCP): ICH (4) ICH GCP implementation: European Union Guideline for Good Clinical Practice (Topic E6) CPMP/ICH/135/95 (final July 17, 1996; effective January 17, 1997) Website: 7/37 (NB: it is a guideline, not a law; has to be incorporated in national laws of member states) 8/36 GOOD CLINICAL PRACTICE: DEFINITION (1) (ICH, 1996) Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. 9/37

16 GOOD CLINICAL PRACTICE: DEFINITION (2) (ICH, 1996) Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible. 10/37 GOOD CLINICAL PRACTICE (ICH) (1) BASED ON (1): World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects First version: 1964 Revised six times since then Most recent version: 2008 (Seoul) 11/37 GOOD CLINICAL PRACTICE (ICH) (2) BASED ON (2): 12/37

17 DECLARATION OF HELSINKI: OBJECTIVES Protection of the rights and safety of human subjects (including protection of privacy) Integrity of data (to prevent fraud) Transparency of conduct of a study (traceability) Reproducible data 13/37 IMPORTANT ASPECTS OF GCP IN GENERAL (1) Strategic planning Standard Operating Procedures Ethics Committee Approval Informed Consent (free will) 14/37 IMPORTANT ASPECTS OF GCP IN GENERAL (2) Well-designed study (Study Protocol; official document) 15/37

18 16/36 IMPORTANT ASPECTS OF GCP IN GENERAL (3) Highly skilled Investigator (documented training!) Well-controlled research equipment (good infrastructure) Monitoring Control of study medication (drug accountability) 17/37 IMPORTANT ASPECTS OF GCP IN GENERAL (4) Good documentation of all stages of study (with change control!) Integrity of data Quality Assurance Archives 18/37

19 IMPORTANT ASPECTS OF GCP IN GENERAL (5) MOST IMPORTANT ASPECT: NOT DOCUMENTED = NOT DONE 19/36 20/36 21/37

20 ICH GUIDELINE FOR GCP (1) Divided into: Glossary The Principles of ICH GCP Institutional Review Board/Independent Ethics Committee (IRB/IEC) Investigator Sponsor Clinical Trial Protocol and Protocol Amendment(s) Investigator s Brochure Essential documents for the conduct of a clinical trial 22/37 ICH GUIDELINE FOR GCP (2) THE PRINCIPLES OF ICH GCP (1): 1. Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory requirement(s). 2. Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits justify the risks. 23/37 ICH GUIDELINE FOR GCP (3) THE PRINCIPLES OF ICH GCP (2): 3. The rights, safety and well-being of the trial subjects are the most important considerations and should prevail over interests of science and society. 4. The available nonclinical and clinical information on an investigational product should be adequate to support the proposed clinical trial. 5. Clinical trials should be scientifically sound; and described in a clear, detailed protocol. 24/37

21 ICH GUIDELINE FOR GCP (4) THE PRINCIPLES OF ICH GCP (3): 6. A trial should be conducted in compliance with the protocol that has received prior Institutional Review Board (IRB) / Independent Ethics Committee (IEC) approval / favourable opinion. 25/37 ICH GUIDELINE FOR GCP (5) THE PRINCIPLES OF ICH GCP (4): 7. The medical care given to, and medical decisions made on behalf of, subjects should always be the responsibility of a qualified physician or, when appropriate, of a qualified dentist. 8. Each individual involved in conducting a trial should be qualified by education, training and experience to perform his or her respective task(s). 27/37

22 ICH GUIDELINE FOR GCP (6) THE PRINCIPLES OF ICH GCP (5): 9. Freely given informed consent should be obtained from every subject prior to clinical trial participation. 10. All clinical trial information should be recorded, handled and stored in a way that allows its accurate reporting, interpretation and verification. 28/37 ICH GUIDELINE FOR GCP (7) THE PRINCIPLES OF ICH GCP (6): 11. The confidentiality of records that could identify subjects should be protected respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s). 12. Investigational products should be manufactured, handled and stored in accordance with applicable good manufacturing practice (GMP). They should be used in accordance with the approved protocol. 29/37 ICH GUIDELINE FOR GCP (8) THE PRINCIPLES OF ICH GCP (7): 13. Systems with procedures that assure the quality of every aspect of the trial should be implemented. 30/37

23 ICH GUIDELINE FOR GCP (9) Who is responsible? Research Ethics Committee Quality and GCPcompliance Data accuracy and integrity Protection of study subject X - X Investigator X X X Sponsor X X X Monitor X X - 31/37 OTHER GUIDELINES (1) LEGISLATION EUROPE Directive 20/2001/EC ( Clinical Trials Directive ) Directive 28/2005/EC ( Good Clinical Practice Directive ) and several Guidances of the European Union 32/37 OTHER GUIDELINES (2) USA Many laws, guidances that have to be obeyed when performing studies for market authorisation in the USA. 33/37

24 OTHER GUIDELINES (3) BUT: The most important guideline is: USE YOUR COMMON SENSE! 34/37 CONCLUSIONS (1) There are differences in different countries but harmonisation (ICH) is imminent. ICH Guideline for GCP is nowadays world standard. EU Directive 2001/20/EC ( Clinical Trials Directive ) and Directive 2005/28/EC ( GCP Directive ) will have great impact. 35/37 CONCLUSIONS (2) GCP contributes to better protection of study participants through Evaluation / approval of protocol by Medical Ethics Committee Only participation after written consent of subject Surveillance of adverse events Protection of privacy of participants 36/37

25 CONCLUSIONS (3) GCP contributes to better reproducible and more reliable data (less misconduct and/or fraud) through Strict compliance with Study Protocol Full documentation of all stages of the study (not documented = not done) Implementation of quality management system SOP s Training In-process quality control Audits by independent Quality Assurance Department Drug accountability 37/37 Archiving

26

27 Vom ICH-GCP-Standard zur deutschen Gesetzgebung für klinische Prüfungen

28

29 VOM ICH-GCP-STANDARD ZUR DEUTSCHEN GESETZGEBUNG FÜR KLINISCHE PRÜFUNGEN Dr. med. Ingrid Klingmann Material erstellt in Zusammenarbeit mit Dr. Frank Wells Consultant Pharmaceutical Physician Ipswich, UK CONTENT What is GCP? History, from the 1930s to the 1990s History, from the 1990s onwards The EC Directives GCP today GCP implementation in German legislation 2/29 Mar /36 3/29 Mar 2011

30 HISTORY (6) 1990s: (a) The International Conference on Harmonisation of Regulatory Requirements for Pharmaceuticals (ICH) was established (1990). The topics selected for harmonisation would be divided into Safety, Quality and Efficacy, with Expert Working Groups discussing the scientific and technical aspects of each harmonisation topic. (b) The World Health Organisation (WHO) published its GCP Guidelines (1995). (c) ICH published its GCP Consolidated Guideline (1996). 4/29 Mar 2011 WHAT IS GCP? Good Clinical Research Practice (GCP) incorporates established ethical and scientific standards for the overall conduct of clinical research projects in human subjects. Compliance with GCP provides public assurance that the research subjects are protected and respected, consistent with the Declaration of Helsinki and other internationally recognised ethical guidelines and ensures the integrity of clinical research data. 5/29 Mar 2011 WHAT IS GCP? The responsibility for GCP is shared by sponsors, investigators and site staff, contract research organisations (CROs), research ethics committees, regulatory authorities and research subjects. 6/29 Mar 2011

31 HISTORY (1) 1930s: A tragic mistake in the formulation of a children's syrup in the USA was the trigger for setting up the product authorisation system under the Food and Drug Administration. 1947: The Nuremberg Code, considered the first document that set out the ethics of experiments involving humans, emphasised the principles of informed consent. 1950s: Government regulations requiring all medicinal products to be registered for sale started in Japan. 7/29 Mar 2011 HISTORY (2) 1960s: The thalidomide tragedy revealed, in many countries in Europe, that the new generation of synthetic drugs, which were revolutionising medicine at the time, had the potential to harm as well as heal. 1964: The World Medical Association published the Declaration of Helsinki as a statement of ethical principles to provide guidance to physicians and other participants in medical research involving human subjects. 8/29 Mar 2011 HISTORY (3) 1970s: A rapid increase in laws, regulations and guidelines for reporting and evaluating the data on safety, quality and efficacy of new medicinal products. But there was no harmonisation or rationalisation. 9/29 Mar 2011

32 HISTORY (4) 1980s: (a) Several different pharmaceutical companies developed guidelines on how to conduct clinical trials. (b) Harmonisation of regulatory requirements was pioneered by the European Community, as the EC (now the European Union) moved towards the development of a single market for pharmaceuticals. 10/29 Mar 2011 HISTORY (5) 1980s: (c) In 1986 the Association of the British Pharmaceutical Industry (ABPI) published policy guidelines on Good Clinical Research Practice. 11/29 Mar s: HISTORY (6) (a) The International Conference on Harmonisation of Regulatory Requirements for Pharmaceuticals (ICH) was established (1990). The topics selected for harmonisation would be divided into Safety, Quality and Efficacy, with Expert Working Groups discussing the scientific and technical aspects of each harmonisation topic. (b) The World Health Organisation (WHO) published its GCP Guidelines (1995). (c) ICH published its GCP Consolidated Guideline (1996). 12/29 Mar 2011

33 THE EUROPEAN UNION (1) 1965: Council Directive 65/65/EEC required the submission of a dossier containing the results of tests and clinical trials. 1975: Council Directive 75/318/EEC laid down uniform rules on the presentation of such dossiers. 13/29 Mar 2011 THE EUROPEAN UNION (2) 2001: Directive 2001/20/EC of the European Commission relates to the implementation of good clinical practice (GCP) in the conduct of clinical trials on medicinal products for human use. [The Clinical Trials Directive] 2005: Directive 2005/28/EC of the European Commission lays down principles and detailed guidelines for good clinical practice (GCP) as regards investigational medicinal products for human use. [The GCP Directive] 14/29 Mar 2011 THE EUROPEAN UNION (3) The legislations released by the European Commission have different legal weight : Regulation = Verordnung : text has to be implemented in national legislation as it stands Directive = Richtlinie : the principles have to be implemented in national legislation but leave the member states flexibility of interpretation and adaptation to national legislation Guidance = Leitfaden, Empfehlung 15/29 Mar 2011

34 THE EUROPEAN UNION (4) EudraLex, Volume 10: vol-10/ Chapter I: Application and application forms Chapter II: Monitoring and pharmacovigilance Chapter III: Quality of the IMP Chapter IV: Inspections Chapter V: Additional information Chapter VI: Legislation 16/29 Mar 2011 THE EUROPEAN UNION (5) EudraLex, Volume 10: Chapter I: Application and application forms CT-1: Detailed guidance for authorisation of a clinical trial and substantial amendment CT-2: Detailed guidance on the application format and documentation to be submitted to ethics committees CT-5: Detailed guidance on the EudraCT Database 17/29 Mar 2011 THE EUROPEAN UNION (6) EudraLex, Volume 10: Chapter II: Monitoring and pharmacovigilance CT-3: Detailed guidance on adverse reaction reporting (SUSARs) CT-4: Detailed guidance on the EudraVigilance Database Q&A specific to AR reporting ICH-E2F: Note for guidance on the development of safety update reports Note: there is NO guidance on monitoring of clinical trials!! 18/29 Mar 2011

35 THE EUROPEAN UNION (7) EudraLex, Volume 10: Chapter V: Additional Information ICH-E6: GCP guideline GCP guideline for advanced therapy medicinal products Recommendations on the content of the Trial Master File Ethical considerations for paediatric clinical trials Guideline on information to be made public from EudraCT 19/29 Mar 2011 THE EUROPEAN UNION (8) EudraLex, Volume 10: Chapter VI: Legislation Directive 2001/20/EC: Clinical Trials Directive Commission Directive 2005/28/EC: GCP Directive Commission Directive 2003/94/EC : GMP Directive 20/29 Mar 2011 DEUTSCHE GESETZGEBUNG (1) In Deutschland werden Gesetze zur klinischen Prüfung und Marktzulassung für Medikamente und Medizinprodukte vom Bundesministerium für Gesundheit erlassen Landesbehörden sorgen mit ihrer Überwachung für die Einhaltung der Gesetze Bundesinstitutionen sorgen für die Umsetzung der Gesetze 21/29 Mar 2011

36 DEUTSCHE GESETZGEBUNG (2) Deutschland hat zwei Institutionen für die Genehmigung von klinischen Prüfungen und die Marktzulassung für neue Medikamente Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) in Bonn Paul Ehrlich Institut in Langen bei Frankfurt 22/29 Mar 2011 DEUTSCHE GESETZGEBUNG (3) Arzneimittelgesetz (AMG) Medizinproduktegesetz (MPG) Verordnungen zu den Gesetzen Bekanntmachungen des BfArM 23/29 Mar 2011 DEUTSCHE GESETZGEBUNG (4) Deutsche Gesetzgebung für klinische Prüfungen 12. AMG-Novelle, am 06. August 2004 in Kraft getreten Ergänzungen in der 14. und 15. AMG-Novelle 4. MPG-Novelle, am 21. März 2010 in Kraft getreten GCP-Verordnung am 11. August 2004 in Kraft getreten Dritte Bekanntmachung des BfArM am 10. August 2006 veröffentlicht 24/29 Mar 2011

37 NOW In 2011, all clinical trials are expected to be conducted to ICH GCP standards. 25/29 Mar 2011 CONCLUSIONS (1) There are differences in different countries but harmonisation (ICH) is progressing. ICH Guideline for GCP is nowadays world standard. EU Directive 2001/20/EC ( Clinical Trials Directive ) and Directive 2005/28/EC ( GCP Directive ) have great impact. 26/29 Mar 2011 CONCLUSIONS (2) German clinical trials legislation has fully implemented the GCP guideline and the Clinical Trials Directive German clinical trial legislation consists of Arzneimittelgesetz, Medizinproduktegesetz, GCP-Verordnung and 3. Bekanntmachung des BfArM 27/29 Mar 2011

38 CONCLUSIONS (3) GCP contributes to better protection of study participants through Evaluation / approval of protocol by Research Ethics Committee Only participation after written consent of subject Surveillance of adverse events Protection of privacy of participants 28/29 Mar 2011 CONCLUSIONS (4) GCP contributes to better reproducible and more reliable data (less misconduct and/or fraud) through Strict compliance with Study Protocol Full documentation of all stages of the study (not documented = not done) Implementation of quality management system SOP s Training In-process quality control Audits by independent Quality Assurance Department Drug accountability Archiving 29/29 Mar 2011

39 Ethische Begutachtung und Ethikkommissionen

40

41 ETHISCHE BEGUTACHTUNG UND ETHIKKOMMISSIONEN Dr. med. Ingrid Klingmann Pharmaplex bvba Brüssel, Belgien CONTENT Ethical aspects in clinical trials How to ensure an ethical randomised clinical trial? German Ethical Review Legislation 2/36 Jan 2011 ETHICAL REVIEW Ethics committees in Gemany review the scientific and ethical aspects of the clinical trial design as well as adherence to all GCP and national legal requirements The basis for their review is the Declaration of Helsinki, The Good Clinical Practice Guideline, the Arzneimittelgesetz and the GCP-Verordnung 3/36 Jan 2011

42 THE RANDOMISED CLINICAL TRIAL (1) The randomized clinical trial is the gold standard of clinical research (Meran, 1978) The randomized, double-blind, placebo-controlled trial is the gold standard for estimating drug treatment effects (Gilbert & Buncher, 2005) The double-blind, randomized, placebo-controlled clinical trial is considered the best method for collecting evidence about diagnostic, therapeutic, or preventive interventions. Well conducted placebo-controlled trials have high internal validity (Glass, 2008) 4/36 Jan 2011 THE RANDOMISED CLINICAL TRIAL (2)..but they lead to major ethical controversies: When is it ethical to randomise? Under which conditions is it ethical to randomise? Is randomisation in the patient s best interest? Does the methodological validity justify the disadvantages for the patients? Is randomisation a suitable method for all types of patients? Is placebo-control ethical? 5/36 Jan 2011 THE DECLARATION OF HELSINKI (1) It is the duty of the physician to promote and safeguard the health of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfillment of this duty. A physician shall act in the patient's best interest when providing medical care In medical research involving human subjects, the well-being of the individual research subject must take precedence over all other interests 6/36 Jan 2011

43 THE DECLARATION OF HELSINKI (2) It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation 7/36 Jan 2011 THE DECLARATION OF HELSINKI (3) Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects 8/36 Jan 2011 THE DECLARATION OF HELSINKI (4) In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest... After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject s freely-given informed consent, preferably in writing 9/36 Jan 2011

Notice: All mentioned inventors have to sign the Report of Invention (see page 3)!!!

Notice: All mentioned inventors have to sign the Report of Invention (see page 3)!!! REPORT OF INVENTION Please send a copy to An die Abteilung Technologietransfer der Universität/Hochschule An die Technologie-Lizenz-Büro (TLB) der Baden-Württembergischen Hochschulen GmbH Ettlinger Straße

Mehr

Institut für Ethik und Geschichte der Medizin Die revidierte Fassung der Deklaration von Helsinki, Fortaleza 2013 des Weltärztebundes

Institut für Ethik und Geschichte der Medizin Die revidierte Fassung der Deklaration von Helsinki, Fortaleza 2013 des Weltärztebundes Die revidierte Fassung der Deklaration von Helsinki, Fortaleza 2013 des Weltärztebundes Urban Wiesing WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Adopted by the 18th WMA General Assembly, Helsinki,

Mehr

POST MARKET CLINICAL FOLLOW UP

POST MARKET CLINICAL FOLLOW UP POST MARKET CLINICAL FOLLOW UP (MEDDEV 2.12-2 May 2004) Dr. med. Christian Schübel 2007/47/EG Änderungen Klin. Bewertung Historie: CETF Report (2000) Qualität der klinischen Daten zu schlecht Zu wenige

Mehr

Darstellung und Anwendung der Assessmentergebnisse

Darstellung und Anwendung der Assessmentergebnisse Process flow Remarks Role Documents, data, tool input, output Important: Involve as many PZU as possible PZO Start Use appropriate templates for the process documentation Define purpose and scope Define

Mehr

WS5: Validierung von computerisierten Systemen im GCP-Umfeld

WS5: Validierung von computerisierten Systemen im GCP-Umfeld Behörde für betrieblichen Arbeits-, Umwelt- und Verbraucherschutz - Dez. 74 AMG WS5: Validierung von computerisierten Systemen im GCP-Umfeld - Regulatorische Anforderungen - 3. Offizielle GAMP 5 Konferenz

Mehr

aqpa Vereinstreffen 15. Okt. 2014, Wien

aqpa Vereinstreffen 15. Okt. 2014, Wien aqpa Vereinstreffen 15. Okt. 2014, Wien EU-GMP-Richtlinie Part II Basic Requirements for Active Substances used as Starting Materials Dr. Markus Thiel Roche Austria GmbH History ICH Richtlinie Q7 Nov.

Mehr

From a Qualification Project to the Foundation of a Logistics Network Thuringia. Logistik Netzwerk Thüringen e.v.

From a Qualification Project to the Foundation of a Logistics Network Thuringia. Logistik Netzwerk Thüringen e.v. From a Qualification Project to the Foundation of a Logistics Network Thuringia Strengthening the role of Logistics through Corporate Competence Development a pilot project by Bildungswerk der Thüringer

Mehr

Cooperation Project Sao Paulo - Bavaria. Licensing of Waste to Energy Plants (WEP/URE)

Cooperation Project Sao Paulo - Bavaria. Licensing of Waste to Energy Plants (WEP/URE) Cooperation Project Sao Paulo - Bavaria Licensing of Waste to Energy Plants (WEP/URE) SMA 15.10.2007 W. Scholz Legal framework Bayerisches Staatsministerium für European Directive on Waste incineration

Mehr

How to develop and improve the functioning of the audit committee The Auditor s View

How to develop and improve the functioning of the audit committee The Auditor s View How to develop and improve the functioning of the audit committee The Auditor s View May 22, 2013 Helmut Kerschbaumer KPMG Austria Audit Committees in Austria Introduced in 2008, applied since 2009 Audit

Mehr

TMF projects on IT infrastructure for clinical research

TMF projects on IT infrastructure for clinical research Welcome! TMF projects on IT infrastructure for clinical research R. Speer Telematikplattform für Medizinische Forschungsnetze (TMF) e.v. Berlin Telematikplattform für Medizinische Forschungsnetze (TMF)

Mehr

ISO 15504 Reference Model

ISO 15504 Reference Model Process flow Remarks Role Documents, data, tools input, output Start Define purpose and scope Define process overview Define process details Define roles no Define metrics Pre-review Review yes Release

Mehr

DVMD Tagung Hannover 2011

DVMD Tagung Hannover 2011 DVMD Tagung Hannover 2011 Vorstellung der Bachelorarbeit mit dem Thema Schwerwiegende Verstöße gegen GCP und das Studienprotokoll in klinischen Studien - Eine vergleichende Analyse der Regularien der EU-Mitgliedsstaaten

Mehr

There are 10 weeks this summer vacation the weeks beginning: June 23, June 30, July 7, July 14, July 21, Jul 28, Aug 4, Aug 11, Aug 18, Aug 25

There are 10 weeks this summer vacation the weeks beginning: June 23, June 30, July 7, July 14, July 21, Jul 28, Aug 4, Aug 11, Aug 18, Aug 25 Name: AP Deutsch Sommerpaket 2014 The AP German exam is designed to test your language proficiency your ability to use the German language to speak, listen, read and write. All the grammar concepts and

Mehr

Wissenswertes zu den jährlichen Sicherheitsberichten bzw. DSURs

Wissenswertes zu den jährlichen Sicherheitsberichten bzw. DSURs Wissenswertes zu den jährlichen Sicherheitsberichten bzw. DSURs Dr. Corina Spreitzer Institut Überwachung, Abteilung Klinische Prüfungen AGES-Gespräch Wien, 29.10.2015 www.basg.gv.at Österreichische Agentur

Mehr

Risk-Managements for Installation, Maintenance and Reprocessing of Medical Devices

Risk-Managements for Installation, Maintenance and Reprocessing of Medical Devices Risk-Managements for Installation, Maintenance and Reprocessing of Medical Devices Laws, Guidelines and Standards Medizinproduktegesetz (MPG) Medizinprodukte-Betreiberverordnung (MBetreibV) Sicherheitsplanverordnung

Mehr

Auswirkungen gesetzlicher Rahmenbedingungen auf universitäre klinische Studien

Auswirkungen gesetzlicher Rahmenbedingungen auf universitäre klinische Studien Auswirkungen gesetzlicher Rahmenbedingungen auf universitäre klinische Studien Armin Koch Institut für Biometrie Medizinische Hochschule Hannover Carl-Neuberg-Str. 1 30625 Hannover Übersicht: 1. In eigener

Mehr

ISO 15504 Reference Model

ISO 15504 Reference Model Prozess Dimension von SPICE/ISO 15504 Process flow Remarks Role Documents, data, tools input, output Start Define purpose and scope Define process overview Define process details Define roles no Define

Mehr

Rollen im Participant Portal

Rollen im Participant Portal Rollen im Participant Portal Stand Februar 2011 Inhaltsverzeichnis 1 Welche Aufteilung existiert grundsätzlich im PP?...3 1.1 Organisation Roles:...3 1.2 Project Roles:...4 1.2.1 1st level: Coordinator

Mehr

Lehrstuhl für Allgemeine BWL Strategisches und Internationales Management Prof. Dr. Mike Geppert Carl-Zeiß-Str. 3 07743 Jena

Lehrstuhl für Allgemeine BWL Strategisches und Internationales Management Prof. Dr. Mike Geppert Carl-Zeiß-Str. 3 07743 Jena Lehrstuhl für Allgemeine BWL Strategisches und Internationales Management Prof. Dr. Mike Geppert Carl-Zeiß-Str. 3 07743 Jena http://www.im.uni-jena.de Contents I. Learning Objectives II. III. IV. Recap

Mehr

EU Verordnung zu Klinischen Prüfungen Teil 1 des Genehmigungsverfahrens Begutachtung durch die Behörde BfArM Elke Stahl

EU Verordnung zu Klinischen Prüfungen Teil 1 des Genehmigungsverfahrens Begutachtung durch die Behörde BfArM Elke Stahl EU Verordnung zu Klinischen Prüfungen Teil 1 des Genehmigungsverfahrens Begutachtung durch die Behörde BfArM Elke Stahl Verordnung (EU) 536/2014 Europaweite Harmonisierung und Vereinfachung Verordnung

Mehr

The DFG Review Process

The DFG Review Process The DFG Review Process Contents 1. Who ensures scientific merit? 2. Who reviews proposals? 3. How are reviewers selected? 4. How does the decision-making process work? 5. What are the DFG's review criteria?

Mehr

Making quality visible. National Quality Certificate for Old Age and Nursing Homes in Austria (NQC)

Making quality visible. National Quality Certificate for Old Age and Nursing Homes in Austria (NQC) Making quality visible. National Quality Certificate for Old Age and Nursing Homes in Austria (NQC) Human Rights Council Genf, 15 September 2015 The Austrian System of Long Term Care System: 2 main components:

Mehr

How does the Institute for quality and efficiency in health care work?

How does the Institute for quality and efficiency in health care work? Health Care for all Creating Effective and Dynamic Structures How does the Institute for quality and efficiency in health care work? Peter T. Sawicki; Institute for Quality and Efficiency in Health Care.

Mehr

HIR Method & Tools for Fit Gap analysis

HIR Method & Tools for Fit Gap analysis HIR Method & Tools for Fit Gap analysis Based on a Powermax APML example 1 Base for all: The Processes HIR-Method for Template Checks, Fit Gap-Analysis, Change-, Quality- & Risk- Management etc. Main processes

Mehr

Corporate Digital Learning, How to Get It Right. Learning Café

Corporate Digital Learning, How to Get It Right. Learning Café 0 Corporate Digital Learning, How to Get It Right Learning Café Online Educa Berlin, 3 December 2015 Key Questions 1 1. 1. What is the unique proposition of digital learning? 2. 2. What is the right digital

Mehr

Exercise (Part XI) Anastasia Mochalova, Lehrstuhl für ABWL und Wirtschaftsinformatik, Kath. Universität Eichstätt-Ingolstadt 1

Exercise (Part XI) Anastasia Mochalova, Lehrstuhl für ABWL und Wirtschaftsinformatik, Kath. Universität Eichstätt-Ingolstadt 1 Exercise (Part XI) Notes: The exercise is based on Microsoft Dynamics CRM Online. For all screenshots: Copyright Microsoft Corporation. The sign ## is you personal number to be used in all exercises. All

Mehr

H. Enke, Sprecher des AK Forschungsdaten der WGL

H. Enke, Sprecher des AK Forschungsdaten der WGL https://escience.aip.de/ak-forschungsdaten H. Enke, Sprecher des AK Forschungsdaten der WGL 20.01.2015 / Forschungsdaten - DataCite Workshop 1 AK Forschungsdaten der WGL 2009 gegründet - Arbeit für die

Mehr

Release Notes BRICKware 7.5.4. Copyright 23. March 2010 Funkwerk Enterprise Communications GmbH Version 1.0

Release Notes BRICKware 7.5.4. Copyright 23. March 2010 Funkwerk Enterprise Communications GmbH Version 1.0 Release Notes BRICKware 7.5.4 Copyright 23. March 2010 Funkwerk Enterprise Communications GmbH Version 1.0 Purpose This document describes new features, changes, and solved problems of BRICKware 7.5.4.

Mehr

1. General information... 2 2. Login... 2 3. Home... 3 4. Current applications... 3

1. General information... 2 2. Login... 2 3. Home... 3 4. Current applications... 3 User Manual for Marketing Authorisation and Lifecycle Management of Medicines Inhalt: User Manual for Marketing Authorisation and Lifecycle Management of Medicines... 1 1. General information... 2 2. Login...

Mehr

CHAMPIONS Communication and Dissemination

CHAMPIONS Communication and Dissemination CHAMPIONS Communication and Dissemination Europa Programm Center Im Freistaat Thüringen In Trägerschaft des TIAW e. V. 1 CENTRAL EUROPE PROGRAMME CENTRAL EUROPE PROGRAMME -ist als größtes Aufbauprogramm

Mehr

Developing the business case for investing in corporate health and workplace partnership indicators and instruments Input

Developing the business case for investing in corporate health and workplace partnership indicators and instruments Input Developing the business case for investing in corporate health and workplace partnership indicators and instruments Input Holger Pfaff Head of the department for Medical Sociology at the Institute of Occupational

Mehr

SELF-STUDY DIARY (or Lerntagebuch) GER102

SELF-STUDY DIARY (or Lerntagebuch) GER102 SELF-STUDY DIARY (or Lerntagebuch) GER102 This diary has several aims: To show evidence of your independent work by using an electronic Portfolio (i.e. the Mahara e-portfolio) To motivate you to work regularly

Mehr

WS 2009/2010 Vorlesung - Spezielles Arzneimittelrecht. Mittwoch, 13. Januar 2010. Pandemie - Teil X

WS 2009/2010 Vorlesung - Spezielles Arzneimittelrecht. Mittwoch, 13. Januar 2010. Pandemie - Teil X Ministerium für,,, und WS 2009/2010 Vorlesung - Spezielles Arzneimittelrecht Mittwoch, 13. Januar 2010 Pandemie - Teil X -Dr. Michael Cramer-2010-01-13 Folie 1 Ministerium für,,, und Klinische Prüfungen

Mehr

Repositioning University Collections as Scientific Infrastructures.

Repositioning University Collections as Scientific Infrastructures. Repositioning University Collections as Scientific Infrastructures. HUMANE Seminar Academic Cultural Heritage: The Crown Jewels of Academia Rome, November 14-16, 2014 Dr. Cornelia Weber Humboldt University

Mehr

Titelbild1 ANSYS. Customer Portal LogIn

Titelbild1 ANSYS. Customer Portal LogIn Titelbild1 ANSYS Customer Portal LogIn 1 Neuanmeldung Neuanmeldung: Bitte Not yet a member anklicken Adressen-Check Adressdaten eintragen Customer No. ist hier bereits erforderlich HERE - Button Hier nochmal

Mehr

Possible Solutions for Development of Multilevel Pension System in the Republic of Azerbaijan

Possible Solutions for Development of Multilevel Pension System in the Republic of Azerbaijan Possible Solutions for Development of Multilevel Pension System in the Republic of Azerbaijan by Prof. Dr. Heinz-Dietrich Steinmeyer Introduction Multi-level pension systems Different approaches Different

Mehr

Incident Management in the Canton of Bern

Incident Management in the Canton of Bern Incident Management in the Canton of Bern KKJPD Workshop Switzerland-Finland 26 February 2015 Kartause Ittingen (TG) Dr. Stephan Zellmeyer, KFO / BSM, Canton of Bern Agenda Federalist system Structure

Mehr

Mitglied der Leibniz-Gemeinschaft

Mitglied der Leibniz-Gemeinschaft Methods of research into dictionary use: online questionnaires Annette Klosa (Institut für Deutsche Sprache, Mannheim) 5. Arbeitstreffen Netzwerk Internetlexikografie, Leiden, 25./26. März 2013 Content

Mehr

GMP Training Course. EU GMP Requirements. Good Distribution Practices

GMP Training Course. EU GMP Requirements. Good Distribution Practices GMP Training Course 20-21 October 2009 EU GMP Requirements Good Distribution Practices Dr. Martin Melzer Dr. Martin Melzer Pharmacist / GMP Inspector Tel.: + 49 (0) 511 9096 450 martin.melzer@gaa-h.niedersachsen.de

Mehr

WP2. Communication and Dissemination. Wirtschafts- und Wissenschaftsförderung im Freistaat Thüringen

WP2. Communication and Dissemination. Wirtschafts- und Wissenschaftsförderung im Freistaat Thüringen WP2 Communication and Dissemination Europa Programm Center Im Freistaat Thüringen In Trägerschaft des TIAW e. V. 1 GOALS for WP2: Knowledge information about CHAMPIONS and its content Direct communication

Mehr

Inspektion am Prüfzentrum Gute Vorbereitung = Gutes Ergebnis?

Inspektion am Prüfzentrum Gute Vorbereitung = Gutes Ergebnis? D A CH Symposium für klinische Prüfungen 07. und 08. März 2016, Freiburg Inspektion am Prüfzentrum Gute Vorbereitung = Gutes Ergebnis? Alexander Mion, Leiter GCP/GVP Inspektorat - Abteilung Klinische Versuche,

Mehr

Customer-specific software for autonomous driving and driver assistance (ADAS)

Customer-specific software for autonomous driving and driver assistance (ADAS) This press release is approved for publication. Press Release Chemnitz, February 6 th, 2014 Customer-specific software for autonomous driving and driver assistance (ADAS) With the new product line Baselabs

Mehr

Environmental management in German institutions of higher education: Lessons learnt and steps toward sustainable management

Environmental management in German institutions of higher education: Lessons learnt and steps toward sustainable management Environmental management in German institutions of higher education: Lessons learnt and steps toward sustainable management Lüneburg, Juni 23/24, 2005 Joachim Müller Sustainable Management of Higher Education

Mehr

Introduction to the diploma and master seminar in FSS 2010. Prof. Dr. Armin Heinzl. Sven Scheibmayr

Introduction to the diploma and master seminar in FSS 2010. Prof. Dr. Armin Heinzl. Sven Scheibmayr Contemporary Aspects in Information Systems Introduction to the diploma and master seminar in FSS 2010 Chair of Business Administration and Information Systems Prof. Dr. Armin Heinzl Sven Scheibmayr Objective

Mehr

Exercise (Part II) Anastasia Mochalova, Lehrstuhl für ABWL und Wirtschaftsinformatik, Kath. Universität Eichstätt-Ingolstadt 1

Exercise (Part II) Anastasia Mochalova, Lehrstuhl für ABWL und Wirtschaftsinformatik, Kath. Universität Eichstätt-Ingolstadt 1 Exercise (Part II) Notes: The exercise is based on Microsoft Dynamics CRM Online. For all screenshots: Copyright Microsoft Corporation. The sign ## is you personal number to be used in all exercises. All

Mehr

Elektronische Identifikation und Vertrauensdienste für Europa

Elektronische Identifikation und Vertrauensdienste für Europa Brüssel/Berlin Elektronische Identifikation und Vertrauensdienste für Europa Wir wären dann soweit --- oder? Thomas Walloschke Director EMEIA Security Technology Office eidas REGULATION No 910/2014 0 eidas

Mehr

Antragsverfahren. Katerina Kotzia, SusAn Call Secretariat

Antragsverfahren. Katerina Kotzia, SusAn Call Secretariat Antragsverfahren Katerina Kotzia, SusAn Call Secretariat Zeitschiene Aktivitäten Termine Launch of the Co-funded Call 04.01.2016 First step: submission of pre-proposals Deadline for pre-proposal submission

Mehr

Labour law and Consumer protection principles usage in non-state pension system

Labour law and Consumer protection principles usage in non-state pension system Labour law and Consumer protection principles usage in non-state pension system by Prof. Dr. Heinz-Dietrich Steinmeyer General Remarks In private non state pensions systems usually three actors Employer

Mehr

Einsatz einer Dokumentenverwaltungslösung zur Optimierung der unternehmensübergreifenden Kommunikation

Einsatz einer Dokumentenverwaltungslösung zur Optimierung der unternehmensübergreifenden Kommunikation Einsatz einer Dokumentenverwaltungslösung zur Optimierung der unternehmensübergreifenden Kommunikation Eine Betrachtung im Kontext der Ausgliederung von Chrysler Daniel Rheinbay Abstract Betriebliche Informationssysteme

Mehr

Act on Human Genetic Testing (Genetic Diagnosis Act; GenDG)

Act on Human Genetic Testing (Genetic Diagnosis Act; GenDG) Legal provisions related to genetic testing in Germany Act on Human Genetic Testing (Genetic Diagnosis Act; GenDG) Holger Tönnies Robert Koch-Institut Genetic Diagnostic Commission Head of Office European

Mehr

Franke & Bornberg award AachenMünchener private annuity insurance schemes top grades

Franke & Bornberg award AachenMünchener private annuity insurance schemes top grades Franke & Bornberg award private annuity insurance schemes top grades Press Release, December 22, 2009 WUNSCHPOLICE STRATEGIE No. 1 gets best possible grade FFF ( Excellent ) WUNSCHPOLICE conventional annuity

Mehr

Post-Market-Surveillance & PMCF Wann ist eine PMCF-Studie angezeigt? PD Dr. med. Ulrich Matern

Post-Market-Surveillance & PMCF Wann ist eine PMCF-Studie angezeigt? PD Dr. med. Ulrich Matern Post-Market-Surveillance & PMCF Wann ist eine PMCF-Studie angezeigt? PD Dr. med. Ulrich Matern Das Gesetz Clinical investigations shall be performed unless it is duly justified to rely on existing clinical

Mehr

Klinische Prüfungen Internationale Rahmenbedingungen Ein Überblick 22 Mai 2014. Sabine Atzor, F. Hoffmann-La Roche Ltd

Klinische Prüfungen Internationale Rahmenbedingungen Ein Überblick 22 Mai 2014. Sabine Atzor, F. Hoffmann-La Roche Ltd Klinische Prüfungen Internationale Rahmenbedingungen Ein Überblick 22 Mai 2014 Sabine Atzor, F. Hoffmann-La Roche Ltd Klinische Prüfung/ Klinischer Versuch von Arzneimitteln am Menschen Untersuchung von

Mehr

Übergeordnete Ziele der EU Clinical Trials Direc6ve

Übergeordnete Ziele der EU Clinical Trials Direc6ve Übergeordnete Ziele der EU Clinical Trials Direc6ve Einführung eines gemeinsamen, koordinierten Assessments bei mulanaaonalen klinischen Prüfungen in der EU Aber kein zentrales Genehmigungsverfahren NaAonale

Mehr

Risk Management Plans & PSURs. Was könnte die Zukunft bringen?

Risk Management Plans & PSURs. Was könnte die Zukunft bringen? Risk Management Plans & PSURs Was könnte die Zukunft bringen? 1 Strategy to better protect public health by strengthening and rationalising EU pharmacovigilance There is an established link between pharmacovigilance

Mehr

EEX Kundeninformation 2007-09-05

EEX Kundeninformation 2007-09-05 EEX Eurex Release 10.0: Dokumentation Windows Server 2003 auf Workstations; Windows Server 2003 Service Pack 2: Information bezüglich Support Sehr geehrte Handelsteilnehmer, Im Rahmen von Eurex Release

Mehr

GIPS 2010 Gesamtüberblick. Dr. Stefan J. Illmer Credit Suisse. Seminar der SBVg "GIPS Aperitif" 15. April 2010 Referat von Stefan Illmer

GIPS 2010 Gesamtüberblick. Dr. Stefan J. Illmer Credit Suisse. Seminar der SBVg GIPS Aperitif 15. April 2010 Referat von Stefan Illmer GIPS 2010 Gesamtüberblick Dr. Stefan J. Illmer Credit Suisse Agenda Ein bisschen Historie - GIPS 2010 Fundamentals of Compliance Compliance Statement Seite 3 15.04.2010 Agenda Ein bisschen Historie - GIPS

Mehr

Compliance und neue Technologien

Compliance und neue Technologien Compliance und neue Technologien Urs Fischer, dipl. WP, CRISC, CISA Fischer IT GRC Beratung und Schulung Heiter bis bewölkt! Wohin steuert die Technologie Just What Is Cloud Computing? Rolle des CIO ändert!

Mehr

2., erweiterte Auflage Haufe-Verlag 2007. 2., erweiterte Auflage, Hogrefe 06/2005. Handbuch Personalentwicklung/September 2004

2., erweiterte Auflage Haufe-Verlag 2007. 2., erweiterte Auflage, Hogrefe 06/2005. Handbuch Personalentwicklung/September 2004 Consultant Profile Anja Beenen (née Weidemann) Profil M Beratung für Human Resources Management GmbH & Co. KG Berliner Straße 131 42929 Wermelskirchen Telephone: (+49) 21 96 / 70 68 204 Fax: (+49) 21 96

Mehr

p^db=`oj===pìééçêíáåñçêã~íáçå=

p^db=`oj===pìééçêíáåñçêã~íáçå= p^db=`oj===pìééçêíáåñçêã~íáçå= Error: "Could not connect to the SQL Server Instance" or "Failed to open a connection to the database." When you attempt to launch ACT! by Sage or ACT by Sage Premium for

Mehr

Support Technologies based on Bi-Modal Network Analysis. H. Ulrich Hoppe. Virtuelles Arbeiten und Lernen in projektartigen Netzwerken

Support Technologies based on Bi-Modal Network Analysis. H. Ulrich Hoppe. Virtuelles Arbeiten und Lernen in projektartigen Netzwerken Support Technologies based on Bi-Modal Network Analysis H. Agenda 1. Network analysis short introduction 2. Supporting the development of virtual organizations 3. Supporting the development of compentences

Mehr

Old People and Culture of Care.

Old People and Culture of Care. Old People and Culture of Care. Palliative and Dementia Care Reflections of a Study Course Elisabeth Wappelshammer Dirk Müller Andreas Heller One Study - Course two Cities two Semesters Berlin Vienna Study

Mehr

Themen für Seminararbeiten WS 15/16

Themen für Seminararbeiten WS 15/16 Themen für Seminararbeiten WS 15/16 Institut für nachhaltige Unternehmensführung Themenblock A: 1) Carsharing worldwide - An international Comparison 2) The influence of Carsharing towards other mobility

Mehr

STRATEGISCHES BETEILIGUNGSCONTROLLING BEI KOMMUNALEN UNTERNEHMEN DER FFENTLICHE ZWECK ALS RICHTSCHNUR FR EIN ZIELGERICHTETE

STRATEGISCHES BETEILIGUNGSCONTROLLING BEI KOMMUNALEN UNTERNEHMEN DER FFENTLICHE ZWECK ALS RICHTSCHNUR FR EIN ZIELGERICHTETE BETEILIGUNGSCONTROLLING BEI KOMMUNALEN UNTERNEHMEN DER FFENTLICHE ZWECK ALS RICHTSCHNUR FR EIN ZIELGERICHTETE PDF-SBBKUDFZARFEZ41-APOM3 123 Page File Size 5,348 KB 3 Feb, 2002 TABLE OF CONTENT Introduction

Mehr

Die ambulante Gesundheitsversorgung in der Schweiz ein Blick von Aussen

Die ambulante Gesundheitsversorgung in der Schweiz ein Blick von Aussen Die ambulante Gesundheitsversorgung in der Schweiz ein Blick von Aussen Reinhard Busse, Prof. Dr. med. MPH FFPH FG Management im Gesundheitswesen, Technische Universität Berlin (WHO Collaborating Centre

Mehr

Password Management. Password Management Guide MF-POS 8

Password Management. Password Management Guide MF-POS 8 Password Management Password Management Guide MF-POS 8 MF-POS8 Einleitung Dieses Dokument beschreibt die Passwortverwaltung des Kassensystems MF-POS 8. Dabei wird zwischen einem Kellner und einem Verwaltungsbenutzer

Mehr

STRATEGISCHES BETEILIGUNGSCONTROLLING BEI KOMMUNALEN UNTERNEHMEN DER FFENTLICHE ZWECK ALS RICHTSCHNUR FR EIN ZIELGERICHTETE

STRATEGISCHES BETEILIGUNGSCONTROLLING BEI KOMMUNALEN UNTERNEHMEN DER FFENTLICHE ZWECK ALS RICHTSCHNUR FR EIN ZIELGERICHTETE BETEILIGUNGSCONTROLLING BEI KOMMUNALEN UNTERNEHMEN DER FFENTLICHE ZWECK ALS RICHTSCHNUR FR EIN ZIELGERICHTETE PDF-SBBKUDFZARFEZ41-SEOM3 123 Page File Size 5,348 KB 3 Feb, 2002 TABLE OF CONTENT Introduction

Mehr

Algorithms for graph visualization

Algorithms for graph visualization Algorithms for graph visualization Project - Orthogonal Grid Layout with Small Area W INTER SEMESTER 2013/2014 Martin No llenburg KIT Universita t des Landes Baden-Wu rttemberg und nationales Forschungszentrum

Mehr

Supplier Questionnaire

Supplier Questionnaire Supplier Questionnaire Dear madam, dear sir, We would like to add your company to our list of suppliers. Our company serves the defence industry and fills orders for replacement parts, including orders

Mehr

KURZANLEITUNG. Firmware-Upgrade: Wie geht das eigentlich?

KURZANLEITUNG. Firmware-Upgrade: Wie geht das eigentlich? KURZANLEITUNG Firmware-Upgrade: Wie geht das eigentlich? Die Firmware ist eine Software, die auf der IP-Kamera installiert ist und alle Funktionen des Gerätes steuert. Nach dem Firmware-Update stehen Ihnen

Mehr

Lehrstuhl für Allgemeine BWL Strategisches und Internationales Management Prof. Dr. Mike Geppert Carl-Zeiß-Str. 3 07743 Jena

Lehrstuhl für Allgemeine BWL Strategisches und Internationales Management Prof. Dr. Mike Geppert Carl-Zeiß-Str. 3 07743 Jena Lehrstuhl für Allgemeine BWL Strategisches und Internationales Management Prof. Dr. Mike Geppert Carl-Zeiß-Str. 3 07743 Jena http://www.im.uni-jena.de Contents I. Learning Objectives II. III. IV. Recap

Mehr

Overall Coordination- and Communication Platform. for electronic and standardised Data-Exchange between. Ports and Hinterland in Rail-Traffic

Overall Coordination- and Communication Platform. for electronic and standardised Data-Exchange between. Ports and Hinterland in Rail-Traffic Overall Coordination- and Communication Platform for electronic and standardised Data-xchange between Ports and Hinterland in Rail-Traffic KoKoBahn Hafenübergreifende Koordinations- und Kommunikationsplattform

Mehr

DIE NEUORGANISATION IM BEREICH DES SGB II AUSWIRKUNGEN AUF DIE ZUSAMMENARBEIT VON BUND LNDERN UND KOMMUNEN

DIE NEUORGANISATION IM BEREICH DES SGB II AUSWIRKUNGEN AUF DIE ZUSAMMENARBEIT VON BUND LNDERN UND KOMMUNEN DIE NEUORGANISATION IM BEREICH DES SGB II AUSWIRKUNGEN AUF DIE ZUSAMMENARBEIT VON BUND LNDERN UND KOMMUNEN WWOM537-PDFDNIBDSIAADZVBLUK 106 Page File Size 4,077 KB 16 Feb, 2002 COPYRIGHT 2002, ALL RIGHT

Mehr

Proseminar - Organisation und Personal Seminar Organisational Theory and Human Resource Management

Proseminar - Organisation und Personal Seminar Organisational Theory and Human Resource Management 1 Proseminar - Organisation und Personal Seminar Organisational Theory and Human Resource Management Veranstaltungsnummer / 82-021-PS08-S-PS-0507.20151.001 Abschluss des Studiengangs / Bachelor Semester

Mehr

Advanced Availability Transfer Transfer absences from HR to PPM

Advanced Availability Transfer Transfer absences from HR to PPM Advanced Availability Transfer Transfer absences from HR to PPM A PLM Consulting Solution Public Advanced Availability Transfer With this solution you can include individual absences and attendances from

Mehr

Demografic Agency for the economy in Lower Saxony. Johannes Grabbe s presentation at the German-British trades union forum in London, 2nd July 2012

Demografic Agency for the economy in Lower Saxony. Johannes Grabbe s presentation at the German-British trades union forum in London, 2nd July 2012 Demografic Agency for the economy in Lower Saxony Johannes Grabbe s presentation at the German-British trades union forum in London, 2nd July 2012 Collaborative project of: Governmental aid: Content 1.

Mehr

Praktische Aspekte zur Einreichung von Klinischen Prüfungen

Praktische Aspekte zur Einreichung von Klinischen Prüfungen Praktische Aspekte zur Einreichung von Klinischen Prüfungen Programm Die praktischen Seiten der Einreichung EudraCT Nummer und xml File EudraLex Volume 10 ICH Kategorisierung Klinischer Prüfungen Leitfaden

Mehr

E-Discovery the EU Data Protection Authorities approach

E-Discovery the EU Data Protection Authorities approach E-Discovery the EU Data Protection Authorities approach Breakout Session Mind the Gap: Bridging U.S. Cross-border E-discovery and EU Data Protection Obligations Dr. Alexander Dix, LL.M. Berlin Commissioner

Mehr

Umrüstung von SMA Wechselrichtern nach SysStabV Bernd Lamskemper

Umrüstung von SMA Wechselrichtern nach SysStabV Bernd Lamskemper Umrüstung von SMA Wechselrichtern nach SysStabV Bernd Lamskemper Disclaimer IMPORTANT LEGAL NOTICE This presentation does not constitute or form part of, and should not be construed as, an offer or invitation

Mehr

Inequality Utilitarian and Capabilities Perspectives (and what they may imply for public health)

Inequality Utilitarian and Capabilities Perspectives (and what they may imply for public health) Inequality Utilitarian and Capabilities Perspectives (and what they may imply for public health) 1 Utilitarian Perspectives on Inequality 2 Inequalities matter most in terms of their impact onthelivesthatpeopleseektoliveandthethings,

Mehr

20 Jahre. Ihr Partner für Veränderungsprozesse. Your Partner for Change. Your Partner for Change

20 Jahre. Ihr Partner für Veränderungsprozesse. Your Partner for Change. Your Partner for Change 100 C 70 M 10 K 55 M 100 Y Offset Your Partner for Change 20 Jahre Ihr Partner für Veränderungsprozesse Your Partner for Change Basel Bern Buchs Genf Luzern Lugano Schindellegi Zürich 20 Jahre im Dienst

Mehr

Redress Procedure in Horizont 2020

Redress Procedure in Horizont 2020 Redress Procedure in Horizont 2020 Informationen zur Redress Procedure sind im Teilnehmerportal unter folgendem Link zu finden: https://webgate.ec.europa.eu/redress-frontoffice/work.iface Die Anmeldung

Mehr

Accounting course program for master students. Institute of Accounting and Auditing http://www.wiwi.hu-berlin.de/rewe

Accounting course program for master students. Institute of Accounting and Auditing http://www.wiwi.hu-berlin.de/rewe Accounting course program for master students Institute of Accounting and Auditing http://www.wiwi.hu-berlin.de/rewe 2 Accounting requires institutional knowledge... 3...but it pays: Lehman Bros. Inc.,

Mehr

European Qualification Strategies in Information and Communications Technology (ICT)

European Qualification Strategies in Information and Communications Technology (ICT) European Qualification Strategies in Information and Communications Technology (ICT) Towards a European (reference) ICT Skills and Qualification Framework Results and Recommendations from the Leornardo-da-Vinci-II

Mehr

Prediction Market, 28th July 2012 Information and Instructions. Prognosemärkte Lehrstuhl für Betriebswirtschaftslehre insbes.

Prediction Market, 28th July 2012 Information and Instructions. Prognosemärkte Lehrstuhl für Betriebswirtschaftslehre insbes. Prediction Market, 28th July 2012 Information and Instructions S. 1 Welcome, and thanks for your participation Sensational prices are waiting for you 1000 Euro in amazon vouchers: The winner has the chance

Mehr

SMS. Eine Übersicht. 2013 Thomas Pink DIESER TEXT DIENT DER NAVIGATION. DC_LFA_PEL_112_v1_0 1/21

SMS. Eine Übersicht. 2013 Thomas Pink DIESER TEXT DIENT DER NAVIGATION. DC_LFA_PEL_112_v1_0 1/21 SMS Eine Übersicht 2013 Thomas Pink DIESER TEXT DIENT DER NAVIGATION DC_LFA_PEL_112_v1_0 1/21 Vortragsziel Information über: - relevante Normen, - Rechtsgrundlagen, sowie praktische Hinweise für die Erstellung

Mehr

Developing a research data centre for Germany: and its IT-guidelines. Dr. Felix F. Schäfer, German Archaeology Institute (DAI) Berlin

Developing a research data centre for Germany: and its IT-guidelines. Dr. Felix F. Schäfer, German Archaeology Institute (DAI) Berlin Developing a research data centre for Germany: and its IT-guidelines Dr. Felix F. Schäfer, German Archaeology Institute (DAI) Berlin http://www.ianus-fdz.de Data processing in archaeology projects / activities:

Mehr

eurex rundschreiben 094/10

eurex rundschreiben 094/10 eurex rundschreiben 094/10 Datum: Frankfurt, 21. Mai 2010 Empfänger: Alle Handelsteilnehmer der Eurex Deutschland und Eurex Zürich sowie Vendoren Autorisiert von: Jürg Spillmann Weitere Informationen zur

Mehr

Application Form ABOUT YOU INFORMATION ABOUT YOUR SCHOOL. - Please affix a photo of yourself here (with your name written on the back) -

Application Form ABOUT YOU INFORMATION ABOUT YOUR SCHOOL. - Please affix a photo of yourself here (with your name written on the back) - Application Form ABOUT YOU First name(s): Surname: Date of birth : Gender : M F Address : Street: Postcode / Town: Telephone number: Email: - Please affix a photo of yourself here (with your name written

Mehr

Security Planning Basics

Security Planning Basics Einführung in die Wirtschaftsinformatik VO WS 2009/2010 Security Planning Basics Gerald.Quirchmayr@univie.ac.at Textbook used as basis for these slides and recommended as reading: Whitman, M. E. & Mattord,

Mehr

Cosmetic experts love to work with Arcaya because it gives them the opportunity to demonstrate their extensive expertise. Cosmetic experts value the

Cosmetic experts love to work with Arcaya because it gives them the opportunity to demonstrate their extensive expertise. Cosmetic experts value the The Secret Arcaya The name Arcaya is synonymous with secret. Arcaya is for women who want to care for their facial skin better and more intensively with special products and targeted, effective problem-solvers.

Mehr

EG-Zertifikat. wurde das Teilsystem (genauer beschrieben im Anhang) the following subsystem (as detailed in the attached annex)

EG-Zertifikat. wurde das Teilsystem (genauer beschrieben im Anhang) the following subsystem (as detailed in the attached annex) _. _ NOTIFIED BODY INTEROPERABILITY EG-Zertifikat EC Certificate EG-Baumusterprufbescheinigung EC Type Examination Certificate Zertifikat-Nummer/ certificate Number: 0893/1/SB/12/RST/DE EN/2201 GemaR,

Mehr

Disclaimer & Legal Notice. Haftungsausschluss & Impressum

Disclaimer & Legal Notice. Haftungsausschluss & Impressum Disclaimer & Legal Notice Haftungsausschluss & Impressum 1. Disclaimer Limitation of liability for internal content The content of our website has been compiled with meticulous care and to the best of

Mehr

Hazards and measures against hazards by implementation of safe pneumatic circuits

Hazards and measures against hazards by implementation of safe pneumatic circuits Application of EN ISO 13849-1 in electro-pneumatic control systems Hazards and measures against hazards by implementation of safe pneumatic circuits These examples of switching circuits are offered free

Mehr

J RG IMMENDORFF STANDORT F R KRITIK MALEREI UND INSPIRATION ERSCHEINT ZUR AUSSTELLUNG IM MUSEUM LU

J RG IMMENDORFF STANDORT F R KRITIK MALEREI UND INSPIRATION ERSCHEINT ZUR AUSSTELLUNG IM MUSEUM LU J RG IMMENDORFF STANDORT F R KRITIK MALEREI UND INSPIRATION ERSCHEINT ZUR AUSSTELLUNG IM MUSEUM LU 8 Feb, 2016 JRISFRKMUIEZAIMLAPOM-PDF33-0 File 4,455 KB 96 Page If you want to possess a one-stop search

Mehr

MASTER THESIS GRADING PROTOCOL FH BFI WIEN

MASTER THESIS GRADING PROTOCOL FH BFI WIEN MASTER THESIS GRADING PROTOCOL FH BFI WIEN Student s name: Examiner s name: Thesis title: The electronic plagiarism check has shown the following percentage of matching content (value in %. Note: About

Mehr

LABOr: Europäisches Knowledge Centre zur beruflichen Ausbildung und Beschäftigung von Menschen mit Lernbehinderungen

LABOr: Europäisches Knowledge Centre zur beruflichen Ausbildung und Beschäftigung von Menschen mit Lernbehinderungen Beschäftigung von Menschen mit Lernbehinderungen EUR/01/C/F/RF-84801 1 Projektinformationen Titel: Projektnummer: LABOr: Europäisches Knowledge Centre zur beruflichen Ausbildung und Beschäftigung von Menschen

Mehr